High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) include cisplatin-based chemotherapy, which improves survival by targeting micrometastatic disease. Immune checkpoint inhibitors, such as atezolizumab and nivolumab, offer alternatives for cisplatin-ineligible patients.
Video Player is loading.
Video content above is prompted by the following:
- What are the adjuvant therapy options for patients with high-risk muscle invasive bladder cancer (ypT2-ypT4a or N+)?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: Patient Counseling
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
MIUC: Risk of Recurrence After Radical Cystectomy
Related Content
